SEC Form 4 · accession 0001104659-17-061561
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin Harshbarger
Officer — General Counsel
Period of report
Oct 6, 2017
Accepted (ET)
Oct 10, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $7.03 | Oct 6, 2017 | A | 75,000 | A | — | Oct 6, 2027 | Common Shares | 75,000 | 75,000 | D |
Explanation of responses
- F1Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F2The options shall vest and become exercisable in three equal annual installments on October 6, 2018, October 6, 2019 and October 6, 2020.